Ensoma disclosed a roughly 50% reduction in headcount as it transitions from platform development toward clinical execution, focusing resources on its lead clinical candidate EN‑374 for X‑linked chronic granulomatous disease. The company said most impacted roles were platform research positions and emphasized that no programs were discontinued. Ensoma launched a Phase 1/2 study for EN‑374 earlier this year and completed a $53 million financing in September to support the clinical program. Management stated the restructuring reallocates investment to oncology and rare‑disease clinical development while preparing nominations for additional clinical candidates in 2026. The company framed the move as common for platform biotechs entering clinical stages, noting it will rehire as clinical needs expand.